[Comparative clinical trial of vaccines against avian influenza].
Scientic-production association "Microgen" has finished 1st phase of clinical trials of candidate vaccines against avian influenza in order to assess their reactogenicity, safety, and immunogenicity. Two vaccines constructed from NIBRG-14 vaccine strain [A/Vietnam/1 194/2004 (H5N1)], obtained from World Health Organization, were studied: "OrniFlu" (inactivated subunit influenza vaccine adsorbed on aluminium hydroxide) and inactivated polymer-subunit influenza vaccine with polyoxydonium (IPSIV). Clinical trial of the vaccines with different quantity of antigen (15, 30, and 45 mcg of H5N1 virus hemagglutinin) was carried out in Influenza Research Institute (St. Petersburg) and in Mechnikov Research Institute of Vaccines and Sera (Moscow). Analysis of results allowed to conclude that both vaccines were safe, well tolerated and characterized by low reactogenicity. Two-doses vaccination schedule was needed to meet required seroconversion and seroprotection rates (> or =1:40 in > or =70% of vaccinated volunteers). "Orni-Flu" vaccine containing 15 mcg of hemagglutinin and optimal quantity of aluminium hydroxide (0.5 mg) in one dose as well as IPSIV containing 45 mcg of hemagglutinin and 0.75 mg of polyoxydonium in one dose were most immunogenic after 2 doses - seroprotection rates in microneutralization assay were 72.2% and 77.0% respectively. Marked influence of aluminium hydroxide content on immunogenicity of the "OrniFlu" vaccine was confirmed in the study. Optimal quantity of adjuvant was 0.5 mg per dose. According to basic concept of vaccine development, preference is given to vaccine that under minimal quantity of antigen induces sufficient specific immune response and is safe in volunteers. "OrniFlu" vaccine containing 15 mcg of H5N1 virus hemagglutinin and optimal quantity of aluminium hydroxide (0.5 mg) corresponded to these requirements that allowed researchers to recommend it for clinical trials of 2nd phase.
Zverev
V V
VV
Katlinskiĭ
A V
AV
Kostinov
M P
MP
Zhirova
S N
SN
Erofeeva
M K
MK
Stukova
M A
MA
Korovkin
S A
SA
Mel'nikov
S Ia
SIa
Semchenko
A V
AV
Mironov
A N
AN
D000276:Adjuvants, Immunologic; D000293:Adolescent; D000328:Adult; D000536:Aluminum Hydroxide; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D006389:Hemagglutinins, Viral; D006801:Humans; D007114:Immunization; D007115:Immunization Schedule; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology*; D007251:Influenza, Human / Q000097:blood / Q000276:immunology*; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009930:Organic Chemicals; D010146:Pain / Q000139:chemically induced; D012426:Russia; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D006389:Hemagglutinins, Viral; D007252:Influenza Vaccines; D009930:Organic Chemicals; D022223:Vaccines, Subunit; C089921:polyoxydonium; D000536:Aluminum Hydroxide